ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.060
-0.040 (-1.90%)
At close: Aug 10, 2026, 4:00 PM EDT
2.055
-0.005 (-0.24%)
After-hours: Aug 10, 2026, 7:34 PM EDT

ALX Oncology Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
20.9623.8526.0928.4829.0423.39
Research & Development
61.8377116.37141.898.460.17
Other Operating Expenses
-0.243.18----
Total Operating Expenses
82.55104.02142.47170.28127.4483.56
Operating Income
-82.55-104.02-142.47-170.28-127.44-83.56
Interest Income
4.073.969.3710.654.280.09
Interest Expense
-1.41-1.6-1.73-1.57-0.24-0.01
Other Non-Operating Income (Expense)
-1-0.04-0.020.39-0.02-0.01
Total Non-Operating Income (Expense)
1.662.337.629.474.020.07
Pretax Income
-80.89-101.7-134.85-160.81-123.42-83.48
Provision for Income Taxes
-----0.060.02
Net Income
-80.89-101.7-134.85-160.81-123.48-83.46
Net Income to Common
-80.89-101.7-134.85-160.81-123.48-83.46
Net Income Growth
------
Shares Outstanding (Basic)
875452434140
Shares Outstanding (Diluted)
875452434140
Shares Change
63.95%2.84%21.37%5.62%0.97%118.05%
EPS (Basic)
-1.13-1.90-2.58-3.74-3.03-2.07
EPS (Diluted)
-1.13-1.90-2.58-3.74-3.03-2.07
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-70.95-84.35-122.36-131.64-90.65-68.77
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.82-1.57-2.35-3.06-2.23-1.71
EBITDA
-82.01-103.32-141.6-169.44-127.09-83.5
EBIT
-82.55-104.02-142.47-170.28-127.44-83.56
Effective Tax Rate
-0.00%0.00%0.00%0.05%-0.03%
SEC Filings: 10-K · 10-Q